Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of puerarin in V crystal form in preparing drug for preventing and/or treating liver injuries caused by diabetes mellitus

A technology of puerarin and diabetes, which is applied in the field of medicine, can solve the problems of inaccurate curative effect and slow onset, and achieve the effect of alleviating fatty liver and lowering blood sugar

Inactive Publication Date: 2019-04-23
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are problems such as slow onset and uncertain curative effect [6]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of puerarin in V crystal form in preparing drug for preventing and/or treating liver injuries caused by diabetes mellitus
  • Application of puerarin in V crystal form in preparing drug for preventing and/or treating liver injuries caused by diabetes mellitus
  • Application of puerarin in V crystal form in preparing drug for preventing and/or treating liver injuries caused by diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Embodiment 1, the effect of crystal V-type puerarin on fructosamine in type 1 diabetic mice

[0048] Experimental method: 100 mice were adaptively fed for 1 week, and 12 were randomly selected as the normal control group (NC), and the rest were used as the diabetes model group. All animals were fasted overnight for 12 hours, and the mice in the model group were intraperitoneally injected with 130 mg·kg at a volume of 0.1 mL / 10 g -1 Streptozocin (STZ) (prepared with pH 4.4 citric acid buffer solution and placed on ice before use), and the mice in the normal control group were only injected with citric acid buffer solution. After 72 hours of STZ injection, the mice were fasted for 4 hours, blood was taken from the tip of the tail, and the fasting blood glucose was measured. Select fasting blood glucose greater than 16.7mmol L -1 The animal is a mouse model of type 1 diabetes. The diabetic mice successfully modeled were randomly divided into the following groups: model ...

Embodiment 2

[0055] Embodiment 2, the effect of crystal V-type puerarin on the glucose tolerance of type 1 diabetic mice

[0056] Experimental method: On the 19th day of administration, an oral glucose tolerance test (OGTT) was performed. Animals were fasted for 4 hours, blood was taken from the inner canthus of the eyes, and glucose was measured by hexokinase method as the blood glucose level at 0 min before sugar administration. Then give 2.5g·kg by gavage according to the volume of 0.1mL / 10g -1 Glucose solution, blood was collected from the inner canthus of the eyes at 30 minutes, 60 minutes and 120 minutes after the glucose was fed, and the blood glucose levels at each time point were measured. Draw the glucose tolerance curve and calculate the area under the curve (AUC) of blood glucose-time, where AUC = 0.25×FBG 0h+0.5×FBG 0.5h+0.75×FBG 1h+0.5×FBG 2h, where FBG 0h means 0h fasting blood glucose levels.

[0057] Experimental results:

[0058] As shown in Table 2, each dose group o...

Embodiment 3

[0062] Embodiment 3, the effect of crystal V puerarin on the liver function of type 1 diabetic mice

[0063] experimental method:

[0064] At the end of the experiment, the animals were weighed, the eyeballs were removed to take blood, anticoagulated with heparin, centrifuged at 5000r for 15min at 4°C, and the supernatant was taken. An automatic biochemical analyzer was used to detect the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

[0065] Experimental results:

[0066] After 3 weeks of administration, ALT and AST (P<0.05, P<0.01) in crystal V puerarin low and middle dose groups decreased significantly, although ALT in high dose group tended to decrease, but the difference was not significant.

[0067] Table 3 Effect of crystal V puerarin on liver index and liver function in type 1 diabetic mice

[0068]

[0069] n=10~12, Mean±SD. * P** P# P## P<0.01 compared with model control group

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of puerarin in a V crystal form in preparing a drug for preventing, treating and / or alleviating hepatic pathological changes caused by diabetes mellitus, especially the hepatic steatosis, fibrosis and the hepatic pathological changes caused by the diabetes mellitus. The diabetes mellitus refers to the diabetes mellitus I and II. The drug is a clinical solid drug prepared from the puerarin in the V crystal form, other active ingredients and an excipient, wherein 1-1000 mg of the pueratin as an active ingredient is taken orally by one patient every day per kgof body weight.

Description

technical field [0001] The invention relates to the effect of crystalline V-type puerarin on preventing and treating liver damage complicated by diabetes, and belongs to the technical field of medicine. Background technique [0002] With changes in people's lifestyles caused by economic development and urbanization, the number of people with diabetes is on the rise in almost all countries. According to the latest research report of the World Health Organization (WHO) in 2016, as of 2014, the number of diabetic patients in the world was as high as 422 million, and it is predicted that it will reach 625 million by 2040. [1] . In the past three decades, the number of diabetic patients in my country has increased nearly tenfold, and now the number of patients with diabetes ranks first in the world [2] . Diabetes mellitus, as a chronic and lifelong metabolic disease, not only seriously affects the quality of life of patients, but also places a heavy burden on their families an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P1/16A61P3/10
CPCA61K31/352
Inventor 杜冠华侯碧玉张莉吕扬赵月蓉强桂芬杨秀颖
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com